Asian Pacific journal of cancer prevention : APJCP · 2025
Role of microRNA-486-5p as Biomarker Response in Cell Line K562 of Chronic Myeloid Leukemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jha Jay Prakash, Sinha Dinesh Kumar, Singh Sanjeet, Kumari Rekha
Аннотация
OBJECTIVE: This study aims to evaluate the efficiency and accuracy of microRNA (miR)-486-5p as a screening and diagnostic tool for chronic myeloid leukemia (CML).
METHODS: The study was performed on K562 cell line. The cell line of the erythroleukemia type originated from a 53-year-old female patient suffering from chronic myelogenous leukemia during a blast crisis. The cells are non-adherent, rounded in shape, and positive for the BCR: ABL1 fusion gene. In addition, we measured the expression of miR-486-5p in peripheral blood monocytes from healthy volunteers and compared the result with Imatinib treated and untreated K562 cell line.
RESULT: As compared to control blood cells from healthy volunteers, there was a statistically significant downregulation of the expression of miR-486-5p in untreated K562 cells (p-value = 0.007). After Imatinib exposure, the miR-486-5p expression was significantly upregulated in K562 cells as compared to treated and untreated K562 cells (p-value = 0.004).
CONCLUSION: Numerous reports demonstrate the role of miRNA in acting as oncogenes or tumor suppressors in various cancers. We have reported an alteration in the expression of miR-486-5p in the CML cell line. The upregulation of miR-486-5p expression in the post-imatinib exposure K562 cell line suggests that miR-486-5p has an onco-suppressor effector role in the BCR-ABL downstream signalling pathway. It is possible to investigate miR-486-5p as a potential biomarker for early CML detection.
METHODS: The study was performed on K562 cell line. The cell line of the erythroleukemia type originated from a 53-year-old female patient suffering from chronic myelogenous leukemia during a blast crisis. The cells are non-adherent, rounded in shape, and positive for the BCR: ABL1 fusion gene. In addition, we measured the expression of miR-486-5p in peripheral blood monocytes from healthy volunteers and compared the result with Imatinib treated and untreated K562 cell line.
RESULT: As compared to control blood cells from healthy volunteers, there was a statistically significant downregulation of the expression of miR-486-5p in untreated K562 cells (p-value = 0.007). After Imatinib exposure, the miR-486-5p expression was significantly upregulated in K562 cells as compared to treated and untreated K562 cells (p-value = 0.004).
CONCLUSION: Numerous reports demonstrate the role of miRNA in acting as oncogenes or tumor suppressors in various cancers. We have reported an alteration in the expression of miR-486-5p in the CML cell line. The upregulation of miR-486-5p expression in the post-imatinib exposure K562 cell line suggests that miR-486-5p has an onco-suppressor effector role in the BCR-ABL downstream signalling pathway. It is possible to investigate miR-486-5p as a potential biomarker for early CML detection.